Category: glioblastoma
Researchers at Fox Chase Cancer Center have demonstrated that a protein called NEDD9 may be required for some of the most aggressive forms of breast cancer to grow. Their findings, based on the study of a mouse model of breast cancer, are presented in a recent issue of Cancer Research, available on-line now.
The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.
BOSTON (August 10, 2009) -- In a study published online in advance of print in Stem Cells, Tufts researchers report that the STAT3 gene regulates cancer stem cells in brain cancer. Cancer stem cells have many characteristics of stem cells and are thought to be the cells that drive tumor formation.
Washington, DC -- Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies.
UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.
AUGUSTA, Ga. -- Distinctive patterns of genes turned off -- or left on -- in healthy versus cancerous cells could enable early screening for many common cancers and maybe help avoid them, Medical College of Georgia scientists say.
CHICAGO -- The brain tumor afflicting Sen. Edward Kennedy -- a glioblastoma -- is the most aggressive and wily form of brain cancer. It has foiled researchers' decades-long efforts to thwart its explosive growth in the brain. The lethal tumor ? the most common brain tumor in humans -- nimbly alters its genes like a quick-change artist to elude treatments to destroy it.
LOS ANGELES (STRICTLY EMBARGOED UNTIL 12:01 A.M. EDT on JULY 1, 2009) -- A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma mulitforme.
ANN ARBOR, Mich. -- University of Michigan scientists have found that a deficiency in a key tumor suppressor gene in the brain leads to the most common type of adult brain cancer. The study, conducted in mice that mimic human cancer, points the way to more effective future treatments and a way to screen for the disease early.
ANN ARBOR, Mich. ? University of Michigan scientists have found that a deficiency in a key tumor suppressor gene in the brain leads to the most common type of adult brain cancer. The study, conducted in mice that mimic human cancer, points the way to more effective future treatments and a way to screen for the disease early.
The following news tips are based on abstracts or posters to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 - June 2, 2008.
Abstract # 9075, 8 a.m. to noon on Monday, June 1, 2009
Antiparasitic drug is promising in animal studies of metastatic melanoma
Glioblastoma Multiform (GBM) is known as an aggressive brain cancer for which there is no cure. But as researchers work to understand this disease, they discover that GBM may an ideal teacher to help us develop safe and effective stem cell therapeutics.
DENVER - Donald O'Rourke, MD, Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine and colleagues, were able to accurately predict the specific genetic mutation that caused brain cancer in a group of patients studied using magnetic resonance imaging (MRI).
DURHAM, N.C. - Duke University researchers have identified a receptor on the surface of cells that may give them another avenue of attack against glioblastoma, the most common and most deadly type of brain cancer.
The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (MGH) researchers.
